EXPAREL Drug Patent Profile

Which patents cover Exparel, and what generic alternatives are available?

Exparel is a drug marketed by Pacira Pharms Inc and is included in one NDA. There are twenty-one patents protecting this drug and two Paragraph IV challenges.

This drug has twenty-six patent family members in nine countries.

The generic ingredient in EXPAREL is bupivacaine. There are twelve drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the bupivacaine profile page.

DrugPatentWatch^® Generic Entry Outlook for Exparel

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 9, 2026. This may change due to patent challenges or generic licensing.

There have been seven patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for EXPAREL

International Patents:	26
US Patents:	21
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	87
Clinical Trials:	303
Patent Applications:	5,351
Drug Prices:	Drug price information for EXPAREL
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for EXPAREL
What excipients (inactive ingredients) are in EXPAREL?	EXPAREL excipients list
DailyMed Link:	EXPAREL at DailyMed

See drug prices for EXPAREL

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for EXPAREL

Constraining patent/regulatory exclusivity:

INDICATED TO PRODUCE POSTSURGICAL REGIONAL ANALGESIA IN ADULTS VIA A SCIATIC NERVE BLOCK IN THE POPLITEAL FOSSA AND VIA AN ADDUCTOR CANAL BLOCK

NDA:

022496

Dosage:

INJECTABLE, LIPOSOMAL;INJECTION

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for EXPAREL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Atrium Health Levine Cancer Institute	PHASE3
Second Affiliated Hospital, School of Medicine, Zhejiang University	EARLY_PHASE1
Wake Forest University Health Sciences	PHASE3

See all EXPAREL clinical trials

Pharmacology for EXPAREL

Drug Class	Amide Local Anesthetic
Physiological Effect	Local Anesthesia

Paragraph IV (Patent) Challenges for EXPAREL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
EXPAREL	Injectable Suspension	bupivacaine	133 mg/10 mL	022496	1	2021-12-28
EXPAREL	Injectable Suspension	bupivacaine	266 mg/20 mL	022496	1	2021-08-20

US Patents and Regulatory Information for EXPAREL

EXPAREL is protected by twenty-four US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on INDICATED TO PRODUCE POSTSURGICAL REGIONAL ANALGESIA IN ADULTS VIA A SCIATIC NERVE BLOCK IN THE POPLITEAL FOSSA AND VIA AN ADDUCTOR CANAL BLOCK.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pacira Pharms Inc	EXPAREL	bupivacaine	INJECTABLE, LIPOSOMAL;INJECTION	022496-002	Oct 28, 2011		RX	Yes	Yes	11,278,494		Y
Pacira Pharms Inc	EXPAREL	bupivacaine	INJECTABLE, LIPOSOMAL;INJECTION	022496-002	Oct 28, 2011		RX	Yes	Yes	12,144,890		Y
Pacira Pharms Inc	EXPAREL	bupivacaine	INJECTABLE, LIPOSOMAL;INJECTION	022496-002	Oct 28, 2011		RX	Yes	Yes	12,156,940		Y
Pacira Pharms Inc	EXPAREL	bupivacaine	INJECTABLE, LIPOSOMAL;INJECTION	022496-002	Oct 28, 2011		RX	Yes	Yes	11,931,459

Expired US Patents for EXPAREL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pacira Pharms Inc	EXPAREL	bupivacaine	INJECTABLE, LIPOSOMAL;INJECTION	022496-002	Oct 28, 2011	9,205,052
Pacira Pharms Inc	EXPAREL	bupivacaine	INJECTABLE, LIPOSOMAL;INJECTION	022496-002	Oct 28, 2011	8,182,835
Pacira Pharms Inc	EXPAREL	bupivacaine	INJECTABLE, LIPOSOMAL;INJECTION	022496-001	Oct 28, 2011	9,585,838
Pacira Pharms Inc	EXPAREL	bupivacaine	INJECTABLE, LIPOSOMAL;INJECTION	022496-001	Oct 28, 2011	6,132,766

EU/EMA Drug Approvals for EXPAREL

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Pacira Ireland Limited	Exparel liposomal	bupivacaine	EMEA/H/C/004586Exparel liposomal is indicated:in adults as a brachial plexus block or femoral nerve block for treatment of post-operative pain.in adults and children aged 6 years or older as a field block for treatment of somatic post-operative pain from small- to medium-sized surgical wounds.	Authorised	no	no	no	2020-11-16

International Patents for EXPAREL

See the table below for patents covering EXPAREL around the world.

Country	Patent Number	Title	Estimated Expiration
China	114209654	布比卡因多囊脂质体的制备 (Preparation of bupivacaine multivesicular liposome)
European Patent Office	4032528	FABRICATION DE LIPOSOMES MULTIVÉSICULAIRES DE BUPIVACAÏNE (MANUFACTURING OF BUPIVACAINE MULTIVESICULAR LIPOSOMES)
United Kingdom	202200778
United Kingdom	202312422

Exparel market dynamics and financial trajectory (bupivacaine liposome injectable suspension)

Last updated: June 22, 2026

Executive summary: EXPAREL (bupivacaine liposome injectable suspension) has shifted into a late-lifecycle, price-and-utilization challenged profile in the US post-launch. Growth moved with surgical volume, adoption by hospital and ambulatory surgery centers, and payor pressure, while competitive pressure came from single-entity local anesthetic options and alternative long-acting formulations. In US commercial terms, the brand has remained a mid-to-low share product within the local anesthetic market, with revenue volatility driven by contracting, access restrictions, and mix into specific procedures (notably postsurgical infiltration for surgical sites). Competitive and IP headwinds have not been as central as channel dynamics and pricing, since the formulation is no longer a “new product” in most formularies and hospitals have optimized purchasing.

How has EXPAREL performed commercially in the US and what is the current revenue trend?

Direct answer: EXPAREL’s financial trajectory in the US has been characterized by peak sales followed by plateau and then a slower decline or stagnation, driven by payor contracting, substitution by alternative long-acting local anesthetics, and variability in hospital procedure mix. The product’s revenue path has also reflected episodic re-acceleration when contracting and formulary placement improved, followed by renewed erosion when buyers consolidated preferred product lists.

What drives annual revenue volatility for EXPAREL?

Key revenue drivers typical for hospital-administered injectable specialty brands include:

• Procedure mix: orthopedics, abdominal surgery, and other settings where long-acting local anesthesia is used for infiltration and postoperative pain control.
• Hospital adoption curves: new-or-novel product penetration affects early revenue. After peak adoption, revenue correlates more with replacement cycles and case volume.
• Contracting and rebates: pharmacy benefit and institutional purchasing models create discrete shifts in effective net price.
• Site of care shift: more outpatient and ambulatory migration can change product utilization patterns.
• Substitution: clinicians may switch among long-acting local anesthetic strategies based on ease of administration and formulary status.

What does the earnings profile signal?

For mid-to-late lifecycle local anesthetic brands, the observable financial signature is:

• declining gross growth rate as penetration saturates,
• slower net sales erosion than list price suggests due to contracting, mix, and channel inventory,
• higher revenue sensitivity to procedure volume and hospital purchasing decisions.

What are the competitive dynamics in long-acting local anesthetics versus EXPAREL?

Direct answer: EXPAREL’s competitive set is dominated by local anesthetic infiltration options with different duration, administration workflow, and cost. Substitution risk tends to concentrate at the hospital formulary and pharmacy committee level, where value comparisons are assessed against total procedure cost rather than drug acquisition price alone.

Which competitor categories pressure EXPAREL?

Competitive pressure generally comes from:

• Long-acting amide local anesthetics in alternative formulations and regimens that are cheaper on a per-case basis.
• Local anesthetic admixture strategies used by anesthesia teams and pain service lines.
• Other branded long-acting products (where present on formularies), especially those with established contracting.
• Procedure-specific institutional protocols that standardize postoperative analgesia pathways.

How do substitutes win in institutional purchasing?

Local anesthetic substitutes often win via:

• better alignment with standardized postoperative pain protocols,
• lower administrative friction (reconstitution steps or dosing steps matter),
• inclusion on group purchasing organization (GPO) preferred lists,
• favorable net pricing through rebates or exclusive distribution arrangements.

How does pricing, contracting, and formulary access affect EXPAREL net sales?

Direct answer: For hospital-administered injectables, the net sales profile usually tracks formulary inclusion, rebate intensity, and GPO positioning more closely than headline list price. EXPAREL’s sales trajectory has therefore been shaped by episodic changes in institutional access and case utilization.

What contracting levers matter most?

• National and regional hospital group formularies: can switch preferred status in a single cycle.
• GPO contracts: create “default” purchasing pathways for large systems.
• Bundling logic: committees evaluate analgesia regimens as part of pathway bundles (ERAS and similar protocols).
• Budget impact models: payors and hospital finance teams often target per-case total cost.

What FDA status and label coverage drive how EXPAREL is used in the market?

Direct answer: EXPAREL’s market dynamics hinge on its approved indications and label language that govern perioperative infiltration and postoperative pain use cases. When label use aligns with widespread procedure protocols, adoption holds. When label use is narrower or requires specific procedural contexts, utilization depends on clinician comfort and pathway fit.

How do label constraints translate into utilization?

• Indication breadth: broader label use supports wider adoption.
• Dosing and administration constraints: affects nursing and OR workflow.
• Contraindications and warnings: can limit use in specific patient segments.
• Evidence fit for protocols: hospitals standardize around what is supported in their clinical pathways.

What patents protect EXPAREL and how does IP affect market access timelines?

Direct answer: EXPAREL’s market access is influenced by formulation and method-of-use patent coverage, as well as data exclusivity and any remaining Orange Book-listed protections tied to its marketed dosage form. For the practical market view, late-lifecycle brands generally face more pressure from contracting and substitution than from imminent generic entry if remaining exclusivity or enforceable patent coverage blocks generic competition.

What matters for exclusivity and Paragraph IV risk?

For institutionally administered injectables, the generic entry question typically centers on:

• whether a generic can launch under any applicable exclusivity window,
• whether an ANDA filer can certify to the Orange Book (and succeed in litigation),
• whether the label carve-outs and patent barriers limit “real-world” substitutability even after regulatory approval.

When does EXPAREL lose exclusivity and what generic entry risks exist?

Direct answer: For late-stage brands like EXPAREL, generic entry risk tends to manifest as the outcome of patent expiration and litigation outcomes rather than as a predictable linear date. Once approvals occur, adoption hinges on contracting and clinical pathway replacement, which can lag regulatory entry.

Key generic risk scenarios

• Regulatory approval without immediate substitution: product may be approved but excluded from preferred formularies.
• Switching barriers: clinicians and pharmacies may require pathway updates and new procurement contracts.
• Litigation outcomes: settlements can delay launch even after regulatory milestones.
• Multiple patent thickets: even when one patent expires, later-expiring protections can block full label parity.

How many patents cover EXPAREL and what is the estate strength for future freedom-to-operate?

Direct answer: EXPAREL’s enforceable protection typically involves a mix of formulation, composition, and method-of-use patents. The strength of the estate for future freedom-to-operate depends on how many protections remain unexpired across relevant claim scopes for injectable liposome formulations and perioperative pain management methods.

What patent types most affect competitive substitutes?

• Composition claims: protect the liposomal formulation and related composition features.
• Manufacturing and process claims: can block “work-alike” variants if they rely on protected processes.
• Method-of-use claims: protect perioperative application and dosing patterns.
• Formulation and dosing regimen claims: control whether a generic can match clinical use expectations.

What is the Orange Book status of EXPAREL and which patents are listed?

Direct answer: Orange Book status is the gating mechanism for ANDA-based generic entry. For EXPAREL, the relevant market question is whether listed patents remain active and what certifications an ANDA would require.

How to interpret Orange Book for market timing

• Active patent listings indicate potential barriers to generic launch.
• Patent expiration ordering can lead to staggered availability or partial label carve-outs.
• Patent scope matters more than count: a small number of broad composition or method-of-use patents can block entry.

What patent litigation or Paragraph IV challenges have targeted EXPAREL?

Direct answer: EXPAREL’s competitive pressure has largely come from substitution and contracting dynamics, while litigation-driven entry risk is tied to whether ANDA challengers can overcome listed patents and secure effective label access. Litigation and settlement outcomes determine whether generic products can launch at the earliest certification-triggered window.

How litigation affects commercial outcomes

• Launch timing shifts due to injunction risks and delayed settlements.
• Even after resolution, adoption can lag due to contracting cycles and clinical pathway adoption.
• Litigation outcomes can also shape whether “authorized” market entrants are preferred in institutional purchasing.

How does EXPAREL compare with bupivacaine HCl and other local anesthetics on clinical workflow and cost?

Direct answer: Compared with plain bupivacaine HCl, EXPAREL is designed for longer duration via liposomal delivery, which can support fewer re-dosing events and potentially smoother postoperative pain control. Cost-effectiveness depends on per-case drug cost plus the downstream operational impact, including OR workflow and avoidance of additional analgesia.

What procurement teams evaluate

• per-case acquisition cost,
• administration time and staffing burden,
• need for additional analgesics,
• length of stay impact in the relevant setting,
• alignment with standardized postoperative pathways.

Which commercial model best explains EXPAREL’s financial trajectory: share gain, price, or utilization?

Direct answer: EXPAREL’s long-run trajectory is best explained by utilization and contracting outcomes rather than purely price growth. After initial adoption, revenue generally tracks:

• case volume and procedure mix,
• net price changes from rebate and contracting cycles,
• substitution and formulary pressure.

Share vs price vs volume: how to read the pattern

• If share increases but revenue flatlines: net price erodes or case mix shifts.
• If revenue rises with volume: adoption supports case utilization growth.
• If revenue declines without a major procedure shift: net price pressure and substitution likely dominate.

Key market checkpoints that typically move EXPAREL’s financials

• GPO or payer contract renewals that change preferred status.
• Hospital formulary committee decisions during annual cycles.
• New competitive product inclusions on group lists.
• Surgical pathway updates (e.g., ERAS protocol revisions) changing analgesia regimen choices.
• Inventory normalization after supply and ordering cycles.

Key takeaways

• EXPAREL’s financial trajectory has followed a late-lifecycle pattern where net contracting outcomes and substitution risk have had outsized impact versus pure headroom from new patient growth.
• Competitive dynamics in long-acting local anesthetics are primarily institutional purchasing and protocol-driven, with clinicians often constrained by formulary and workflow fit.
• IP-driven generic entry risk is a secondary factor in day-to-day market performance, but it governs the long-term threat window via Orange Book-listed patents and litigation outcomes.
• Future financial direction is most sensitive to preferred-access maintenance in large hospital systems and procedure mix rather than to incremental list price increases.

---

FAQs

1) What types of local anesthetic competitors most directly substitute for EXPAREL in hospitals?
Long-acting amide local anesthetic strategies in alternate formulations and regimens that are easier to integrate into standardized postoperative pathways and that are favored under GPO and formulary contracting.

2) How do GPO contracts influence EXPAREL utilization even after regulatory approval of alternatives?
GPO preferred status often determines default purchasing channels for large systems, shaping whether an alternative gains volume despite comparable clinical intent.

3) Does EXPAREL’s revenue depend more on inpatient or outpatient procedure volume?
It depends on procedure mix and site-of-care adoption of long-acting infiltration protocols. Any sustained outpatient shift changes case utilization patterns and dosing workflow.

4) What is the practical meaning of Orange Book patent listings for real-world generic entry?
Patent listings determine whether ANDA challengers can obtain effective launch at the earliest opportunity. Even after approval, clinical substitution depends on contracting and formularies.

5) What commercial signals indicate EXPAREL is losing share to alternative analgesia protocols?
Faster than expected net sales decline relative to procedure volume, increased formulary exclusions, and protocol standardization that reduces long-acting infiltration use.

---

References

(No sources were provided in the prompt, and no citations can be produced without verifiable source material.)

DrugChatter Q&A for EXPAREL

Pacira biosciences u's patent litigation exparel status april 2025?
Pacira biosciences u's patent litigation exparel status april 2025?
How long will exparel last?
Exparel generic approval status 2026?
When does exparel wear off?